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and utility, providing an opportunity to evaluate esti-
mates of utility from physical function. METHODS: A
total of 2070 patients with active RA participated in 4
clinical trials (ARMADA, DE011, DE019 and STAR).
The Health Assessment Questionnaire Disability Index
(HAQ) measured physical function for all patients and
the Health Utilities Index Mark-3 (HUI3) measured
utility for 2000 patients at baseline and months 3 and 6.
HAQ scores range from 0 (good physical function) to 3.
HUI3 was regressed on HAQ using both repeated
measure mixed models and cross-sectional models 
controlling for age, sex, disease duration, clinical trial 
and fatigue (measured by the Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F)). The cross-
sectional models used end-of-study data with Last Obser-
vation Carried Forward (LOCF) imputation. These
analyses include the 1990 patients with non-missing
values for these variables. RESULTS: The mixed models
and the cross-sectional models provided almost identical
coefﬁcient estimates. Disease duration and trial were 
not signiﬁcant and were deleted from the model. Age 
(in years) was statistically signiﬁcant but trivial (b =
0.00087). The basic estimated cross-sectional model was:
HUI3 = 0.76–0.28*HAQ + 0.05*FEMALE (p < 0.0001
for each regressor, Adj. R2 = 0.49). However, the rela-
tionship between HUI3 and HAQ appears to be nonlin-
ear: coefﬁcients for HAQ-squared and HAQ-cubed were
signiﬁcant (p = 0.013 and p = 0.003, respectively) when
added to the regression. Adding FACIT-F to the basic
cross-sectional model substantially improved model ﬁt
(Adj. R2 = 0.63). CONCLUSIONS: The basic algorithm
developed in this study is consistent with published pre-
dictions of utility from HAQ (Kobelt et al., Arthritis and
Rheumatism, 1999). However, these algorithms’ predic-
tions are limited and should only be used when direct
utility scores are not available.
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OBJECTIVES: During the last ten years the inﬂuence 
of pharmacoeconomics has increased in decision-making.
Due to budget constraints, decision makers often have to
choose which intervention is given priority, for example,
using league tables. The current practice of discounting
both health and monetary beneﬁts at the same rate places
a higher priority on direct medical interventions, with
health beneﬁts occurring immediately. Due to this, pre-
ventive interventions such as vaccination strategies are
possibly under-appreciated, leading to inconsistencies.
Some researchers have suggested to not discount health
beneﬁts at all. We developed a novel approach combin-
ing the rationales underlying both theories of fully and
not-at-all discounting of health beneﬁts. We illustrate 
our novel approach with the conjugate meningococcal
B/C vaccine for newborns in the Netherlands.
METHODS: Firstly, we discard the relevance of the
Keeler-Cretin paradox for day-to-day practice. Secondly,
we note that by discounting the analyst implicitly corrects
for a number of uncertainties and preferences, which are
among others time preference and force of innovation.
Our novel approach appreciates these factors, but also
elaborates on the uncertainty that is already implicitly
covered in the concept of life-years gained, which is part
of the QALY assessment. RESULTS: Our illustration 
for vaccination with the conjugate meningococcal B/C
vaccine renders estimates per QALY gained of €16,000
(monetary ﬁgures and QALYs discounted at 4%), €7000
(monetary ﬁgures discounted at 4%, QALYs non-
discounted) and approximately €10,000 (monetary
ﬁgures at 4% and QALYs according to the novel
approach). CONCLUSIONS: We have developed a novel
approach for discounting health beneﬁts that may be 
considered a consensus approach between fully and 
not-at-all discounting of health beneﬁts. The method 
can be applied to vaccines. Its application may ensure a
more proper pharmacoeconomic valuing of vaccination 
strategies.
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OBJECTIVES: In the Netherlands, the incidence of
meningococcal C infections has strongly increased during
the last years. Should the Netherlands follow the UK 
and start a large-scale meningococcal C vaccination cam-
paign? We calculated the health effects and costs of such
a vaccination program. METHODS: The health effects,
the costs and savings, as well as the cost-effectiveness of
vaccinating all persons aged 14 months to 19 years in the
Netherlands against meningococcal C infection was esti-
mated, from a societal perspective using a decision ana-
lytic model. Data were derived from the Netherlands
Reference Laboratory for Bacterial Meningitis, the Dutch
costing guidelines, PRISMANT Healthcare, and national
and international literature. Direct and indirect costs
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(friction cost method) were considered at 1998 price
levels. Future costs were always discounted at 4% while
future effects (QALYs and LYG) were only discounted 
for computing cost-effectiveness ratios. The study time
horizon was 77 years. RESULTS: The vaccination
program would prevent 228 deaths, 92 severe sequelae
(amputations and neurological sequelae) and render
11,330 life years and 13,470 QALYs (no discounting). 
It would cost €75.6 million and avert €27.5 million 
direct costs and €0.4 million indirect costs. The cost-
effectiveness ratio is €11,830/QALY or €14,070/LYG,
when indirect costs are excluded. Considering indirect
costs leads to slightly better ratios: €11,730/QALY or
€13,950/LYG. These results are sensitive to the incidence
of meningococcal C infections, the discount rate of health
effects and the vaccine’s protection duration. CONCLU-
SIONS: The vaccination program renders a signiﬁcant
health gain and is cost-effective as its cost-effectiveness
ratios lie signiﬁcantly below the Dutch cut-off point for
vaccines. These results played an important role in the
Dutch government’s decision to implement this vaccina-
tion program in June 2002.
IN6
PRIMARY CARE PRESCRIBING AND ANTIBIOTIC
RESISTANCE:WHAT IS THE ADDED VALUE OF
PERSON SPECIFIC DATA ABOUT ANTIBIOTIC
PRESCRIBING COMPARED WITH EXISTING,
PRACTICE LEVEL INFORMATION?
Davey PG1,Wei L1, Donnan P1, Clark R2
1University of Dundee, Dundee, United Kingdom;
2Information and Statistics Division of the Common Services
Agency, Edinburgh, United Kingdom
OBJECTIVE: Antibiotic resistance is a major public
health problem. In the UK prescribing data are currently
routinely available at the level of a primary care practice.
There are both ﬁnancial and data protection barriers to
analysis of data about individuals. The aim of this study
was to test the null hypothesis that, in comparison with
practice level data, there is no added value to patient level
data for measurement of the association between anti-
biotic prescribing and resistance. METHODS: We per-
formed a cross sectional study that linked data about
resistance to trimethoprim in bacteria isolated from urine
samples to prescribing of trimethoprim and other antibi-
otics. We used a random coefﬁcient model with random
and ﬁxed effects, effectively a multi-level model with two
levels: primary care practice and individual patient.
RESULTS: The study included 31 practices with a total
study population of approximately 179,000 people. The
population of a single practice ranged from 1386 to
10,479. There was considerable variation between prac-
tices in both the prevalence of trimethoprim resistance
(from 15% to 50% of bacteria isolated) and trimetho-
prim prescribing (from 71 prescriptions to 312 prescrip-
tions per 100 people in the practice). Nonetheless, in a
multivariate analysis there was no relationship between
variation in prescribing and resistance (p = 0.2717). In
contrast, at the patient level there was a highly signiﬁcant
relationship between trimethoprim resistance and prior
exposure to trimethoprim (p < 0.0001) and antibiotics
other than trimethoprim (p = 0.0128). CONCLUSIONS:
Analysis of practice level data obscures important rela-
tionships between antibiotic prescribing and resistance.
This is an example of the ecological fallacy, which
assumes that differences in exposure at the population
level indicate similar differences in exposure to the indi-
viduals within the population. Our results are an impor-
tant demonstration of the added value of individual
patient data for research on the outcomes of prescribing.
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OBJECTIVES: As new medications for migraine are
introduced, it is imperative that valid tools exist to
measure their impact on patient reported outcomes. The
objective of this project was to develop a Migraine Impact
on Functioning (MIF) Tool based on the “body and mind
functioning (BMF)” and “activity and participation (AP)”
framework presented in the ICIDH2. METHODS: The
tool was developed using a multi-step process ﬁrst pro-
posed by Guyatt. 1) Researchers generated an extensive
list of potential items based on focus groups in Germany
and the US and on review of literature. An item reduc-
tion survey was designed including 71 BMF items and 50
AP items. 2) The item reduction survey assessing the fre-
quency and importance of each item was administered to
samples of migraineurs in Germany (n = 153) and the US
(n = 148). 3) Item reduction was completed by selecting
items with high frequency-weighted importance and by
further analyzing these items using Principal Component
analysis. Differences between items selected in the two
populations were compared to determine if one tool could
meet the needs of both. RESULTS: While results from the
German and US populations identiﬁed BMF items as
important, principal components analysis found similar-
ity in the nature of the factors identiﬁed. In the US, a four-
factor, 13-item model was identiﬁed, including: “energy”,
“intolerance to stimulus”, “emotional impact”, and
“attention/psychomotor issues”. In Germany, a 3-factor,
12-item model was found including “attention/cogni-
tion”, “intolerance to stimulus”, and “emotional issues”.
CONCLUSION: Given the notable overlap in the factors
identiﬁed in the two nations, we believe that the differ-
ence in individual item selection is a product of small
translational or interpretational difference rather than an
